Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 3, 2018 (9 years ago)

Gleevec 100 mg tablet NDC 00078-0401-34 30 days supply

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Processing Controls.

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Gleevec 100 mg tablet NDC 00078-0401-34 30 days supply

Affected NDC 0078-0401-34

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Gleevec
imatinib mesylate
NDC 00078-0401
100 mg/1 Tablet
Oral
Novartis Pharmaceuticals Corporation Rx
Recalling firm
Kroger Specialty Pharmacy, Inc.
NDC code
00078-0401-34
Origin
MS, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0782-2018 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by Kroger Specialty Pharmacy, Inc.

All 2018 recalls

Other cgmp deviation recalls from 2018

All cgmp deviation recalls
Class II · Moderate risk

Oxygen

CGMP Deviations

Terminated cGMP deviation Roberts Home Medical LLC D-1002-2019
Class II · Moderate risk

Cidofovir Dihydrate

CGMP Deviations: Active Pharmaceutical Ingredient (API) manufacturer is on FDA Import Alert.

Terminated cGMP deviation LGM Pharma LLC D-0486-2019